Advanced HR-Positive Breast Cancer: Oral SERDs in Focus
Join us for a live discussion on oral selective estrogen receptor degraders (SERDs) in advanced breast cancer (BC), designed to encourage the exchange of ideas between leaders in the field and attendees. Moderator: Paolo Tarantino, MD, PhD Faculty: Eva Ciruelos, MD, PhD Faculty: Valentina Guarneri, MD, PhD This event is EBAC accredited. Click the link to view the Accreditation and Disclosure details before participating: https://www.medscape.org/viewarticle/... Supported by an independent educational grant from AstraZeneca
▶︎
Estrogen Receptors & HER2/neu Receptors in Breast Cancer (a TUTORIAL from Oster Oncology)
▶︎
Oral SERDs Explained: A New Option for Breast Cancer Patients
▶︎
MSPP Dialogue series - What innovative models for financing antimicrobial development?
▶︎
Breast Cancer: MUST know details (ER, PR, HER2, Ki67, etc)
▶︎
How treatment for early-stage breast cancer has changed
▶︎
NIHR MLTC CNC Methodologies Webinar - Background to MLTC Research
▶︎
What are some of the key issues facing Australia? - World Questions podcast, BBC World Service
▶︎
Can you start HRT after 60? What the evidence shows
▶︎
Oncotype DX for Breast Cancer Explained: How it Guides Treatment Decisions
▶︎
the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer - Issue 8
▶︎
The Real Reason I Stopped Being a Surgeon
▶︎
Launch of the Community of Practice CoP on Advancing Refugee Influence Across GRF Pledges
▶︎
The Foot Doctor: What Your Feet Reveal About How Long You'll Live
▶︎
What do tech pioneers think about the AI revolution? - The Engineers, BBC World Service
▶︎
Meet The 'Twins' Born With Different Dads! | This Morning
▶︎
Selective Estrogen Receptor Degraders (SERDs) in Hormone Receptor Positive Breast Cancer
▶︎
What Is DCIS? The Breast Cancer Diagnosis That's Not Quite Cancer
▶︎
This cell just changed biology
▶︎
The 3 foods you're eating daily that fuel cancer growth | Dr William Li
▶︎